Skip to main content

Table 3 Demographics, specific IgE and symptom scores in subjects according to clinical benefit

From: Clinical efficacy of sublingual immunotherapy is associated with restoration of steady-state serum lipocalin 2 after SLIT: a pilot study

Parameter Median (Min,Max) non-responders, n = 15 responders, n = 26 t test
 Age, y 24.4 (20.5, 42.8) 26.4 (20.0, 53.4) 0.859
 women/men 9/6 14/12  
Before SLIT
 Der f - IgE, kUA/l 15 (2.8, 67.9) 13 (0.9, > 100) 0.904
 TNSS 6.5 (3.8, 10.3) 7.7 (5.4, 11.8) 0.023
After SLIT
 Der f - IgE, kUA/l 24.9 (2.2, > 100) 25.8 (1.3, > 100) 0.303
 TNSS 8.1 (4.7, 12.0) 3.8 (0.5, 7.3) 3 × 10^-9
Absolute change (after-before)
 Der f - IgE, kUA/l 1.7 (−40.3, 84.3) 6.2 (−14.5, 81.5) 0.310
 TNSS 1.5 (−1.3,3.2) −4.2 (−8.5, − 1.8) 2 × 10^-14
% improvement −21 (−56, 18) 58 (20, 92) 4 × 10^-15
  1. TNSS total nasal symptom score